FDA approves Roche’s Enspryng for thyroid eye disease
The FDA approved Roche unit Genentech’s Enspryng for adults with thyroid eye disease. It is the first at-home subcutaneous treatment for the condition, with maintenance dosing every four weeks.
1. FDA approval
The FDA approved Roche unit Genentech’s Enspryng for adults with thyroid eye disease. Enspryng is the first at-home subcutaneous treatment for the condition, with maintenance dosing every four weeks.
